These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 38927459)

  • 1. Synthesis and Characterization of Click Chemical Probes for Single-Cell Resolution Detection of Epichaperomes in Neurodegenerative Disorders.
    Bay S; Digwal CS; Rodilla Martín AM; Sharma S; Stanisavljevic A; Rodina A; Attaran A; Roychowdhury T; Parikh K; Toth E; Panchal P; Rosiek E; Pasala C; Arancio O; Fraser PE; Alldred MJ; Prado MAM; Ginsberg SD; Chiosis G
    Biomedicines; 2024 Jun; 12(6):. PubMed ID: 38927459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemical probes and methods for single-cell detection and quantification of epichaperomes in hematologic malignancies.
    Merugu S; Sharma S; Kaner J; Digwal C; Sugita M; Joshi S; Taldone T; Guzman ML; Chiosis G
    Methods Enzymol; 2020; 639():289-311. PubMed ID: 32475406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unraveling the Mechanism of Epichaperome Modulation by Zelavespib: Biochemical Insights on Target Occupancy and Extended Residence Time at the Site of Action.
    Sharma S; Joshi S; Kalidindi T; Digwal CS; Panchal P; Lee SG; Zanzonico P; Pillarsetty N; Chiosis G
    Biomedicines; 2023 Sep; 11(10):. PubMed ID: 37892973
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety, Tolerability and Pharmacokinetics of Icapamespib, a Selective Epichaperome Inhibitor, in Healthy Adults.
    Silverman MH; Duggan S; Bardelli G; Sadler B; Key C; Medlock M; Reynolds L; Wallner B
    J Prev Alzheimers Dis; 2022; 9(4):635-645. PubMed ID: 36281667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis of
    Sharma S; Kalidindi T; Joshi S; Digwal CS; Panchal P; Burnazi E; Lee SG; Pillarsetty N; Chiosis G
    STAR Protoc; 2022 Jun; 3(2):101318. PubMed ID: 35496791
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemical tools for epichaperome-mediated interactome dysfunctions of the central nervous system.
    Bolaender A; Zatorska D; He H; Joshi S; Sharma S; Digwal CS; Patel HJ; Sun W; Imber BS; Ochiana SO; Patel MR; Shrestha L; Shah SK; Wang S; Karimov R; Tao H; Patel PD; Martin AR; Yan P; Panchal P; Almodovar J; Corben A; Rimner A; Ginsberg SD; Lyashchenko S; Burnazi E; Ku A; Kalidindi T; Lee SG; Grkovski M; Beattie BJ; Zanzonico P; Lewis JS; Larson S; Rodina A; Pillarsetty N; Tabar V; Dunphy MP; Taldone T; Shimizu F; Chiosis G
    Nat Commun; 2021 Aug; 12(1):4669. PubMed ID: 34344873
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of Native-PAGE for the Identification of Epichaperomes in Cell Lines.
    Roychowdhury T; Santhaseela AR; Sharma S; Panchal P; Rodina A; Chiosis G
    Methods Mol Biol; 2023; 2693():175-191. PubMed ID: 37540435
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting stressor-induced dysfunctions in protein-protein interaction networks via epichaperomes.
    Ginsberg SD; Sharma S; Norton L; Chiosis G
    Trends Pharmacol Sci; 2023 Jan; 44(1):20-33. PubMed ID: 36414432
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phosphorylation-Driven Epichaperome Assembly: A Critical Regulator of Cellular Adaptability and Proliferation.
    McNutt SW; Roychowdhury T; Pasala C; Nguyen HT; Thornton DT; Sharma S; Botticelli L; Digwal CS; Joshi S; Yang N; Panchal P; Chakrabarty S; Bay S; Markov V; Kwong C; Lisanti J; Chung SY; Ginsberg SD; Yan P; DeStanchina E; Corben A; Modi S; Alpaugh M; Colombo G; Erdjument-Bromage H; Neubert TA; Chalkley RJ; Baker PR; Burlingame AL; Rodina A; Chiosis G; Chu F
    Res Sq; 2024 Apr; ():. PubMed ID: 38645031
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The penalty of stress - Epichaperomes negatively reshaping the brain in neurodegenerative disorders.
    Ginsberg SD; Joshi S; Sharma S; Guzman G; Wang T; Arancio O; Chiosis G
    J Neurochem; 2021 Dec; 159(6):958-979. PubMed ID: 34657288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phosphorylation-driven epichaperome assembly is a regulator of cellular adaptability and proliferation.
    Roychowdhury T; McNutt SW; Pasala C; Nguyen HT; Thornton DT; Sharma S; Botticelli L; Digwal CS; Joshi S; Yang N; Panchal P; Chakrabarty S; Bay S; Markov V; Kwong C; Lisanti J; Chung SY; Ginsberg SD; Yan P; De Stanchina E; Corben A; Modi S; Alpaugh ML; Colombo G; Erdjument-Bromage H; Neubert TA; Chalkley RJ; Baker PR; Burlingame AL; Rodina A; Chiosis G; Chu F
    Nat Commun; 2024 Oct; 15(1):8912. PubMed ID: 39414766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epichaperome inhibition targets TP53-mutant AML and AML stem/progenitor cells.
    Carter BZ; Mak PY; Muftuoglu M; Tao W; Ke B; Pei J; Bedoy AD; Ostermann LB; Nishida Y; Isgandarova S; Sobieski M; Nguyen N; Powell RT; Martinez-Moczygemba M; Stephan C; Basyal M; Pemmaraju N; Boettcher S; Ebert BL; Shpall EJ; Wallner B; Morgan RA; Karras GI; Moll UM; Andreeff M
    Blood; 2023 Sep; 142(12):1056-1070. PubMed ID: 37339579
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Pretargeted Imaging Strategy for Immune Checkpoint Ligand PD-L1 Expression in Tumor Based on Bioorthogonal Diels-Alder Click Chemistry.
    Qiu L; Tan H; Lin Q; Si Z; Mao W; Wang T; Fu Z; Cheng D; Shi H
    Mol Imaging Biol; 2020 Aug; 22(4):842-853. PubMed ID: 31741201
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The epichaperome is a mediator of toxic hippocampal stress and leads to protein connectivity-based dysfunction.
    Inda MC; Joshi S; Wang T; Bolaender A; Gandu S; Koren Iii J; Che AY; Taldone T; Yan P; Sun W; Uddin M; Panchal P; Riolo M; Shah S; Barlas A; Xu K; Chan LYL; Gruzinova A; Kishinevsky S; Studer L; Fossati V; Noggle SA; White JR; de Stanchina E; Sequeira S; Anthoney KH; Steele JW; Manova-Todorova K; Patil S; Dunphy MP; Pillarsetty N; Pereira AC; Erdjument-Bromage H; Neubert TA; Rodina A; Ginsberg SD; De Marco Garcia N; Luo W; Chiosis G
    Nat Commun; 2020 Jan; 11(1):319. PubMed ID: 31949159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. First-in-Human Trial of Epichaperome-Targeted PET in Patients with Cancer.
    Dunphy MPS; Pressl C; Pillarsetty N; Grkovski M; Modi S; Jhaveri K; Norton L; Beattie BJ; Zanzonico PB; Zatorska D; Taldone T; Ochiana SO; Uddin MM; Burnazi EM; Lyashchenko SK; Hudis CA; Bromberg J; Schöder HM; Fox JJ; Zhang H; Chiosis G; Lewis JS; Larson SM
    Clin Cancer Res; 2020 Oct; 26(19):5178-5187. PubMed ID: 32366671
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early Diagnosis of Neurodegenerative Diseases: What Has Been Undertaken to Promote the Transition from PET to Fluorescence Tracers.
    Bisi N; Pinzi L; Rastelli G; Tonali N
    Molecules; 2024 Feb; 29(3):. PubMed ID: 38338465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Naringenin: A prospective therapeutic agent for Alzheimer's and Parkinson's disease.
    Goyal A; Verma A; Dubey N; Raghav J; Agrawal A
    J Food Biochem; 2022 Dec; 46(12):e14415. PubMed ID: 36106706
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cell models for Alzheimer's and Parkinson's disease: At the interface of biology and drug discovery.
    Cetin S; Knez D; Gobec S; Kos J; Pišlar A
    Biomed Pharmacother; 2022 May; 149():112924. PubMed ID: 36068783
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Selective stimulations and lesions of the rat brain nuclei as the models for research of the human sleep pathology mechanisms].
    Šaponjić J
    Glas Srp Akad Nauka Med; 2011; (51):85-97. PubMed ID: 22165729
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Innovative Therapeutic Strategies in Alzheimer's Disease: A Synergistic Approach to Neurodegenerative Disorders.
    Niazi SK; Magoola M; Mariam Z
    Pharmaceuticals (Basel); 2024 Jun; 17(6):. PubMed ID: 38931409
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.